{
    "clinical_study": {
        "@rank": "51977", 
        "acronym": "CLARITY I", 
        "arm_group": [
            {
                "arm_group_label": "Orbital Atherectomy System", 
                "arm_group_type": "Experimental", 
                "description": "Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)"
            }, 
            {
                "arm_group_label": "Balloon Angioplasty", 
                "arm_group_type": "Active Comparator", 
                "description": "Balloon Angioplasty (BA) alone"
            }
        ], 
        "brief_summary": {
            "textblock": "CLARITY I is a pilot study to identify the clinically appropriate endpoint(s) of a larger,\n      statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia\n      (CLI)."
        }, 
        "brief_title": "Complete Lesion Assessment With Fractional ffR and IVUS TechnologY", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Peripheral Artery Disease", 
            "Critical Limb Ischemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "50 subjects will be randomized 1:1 to Orbital Atherectomy (OA) performed with Cardiovascular\n      Systems, Inc.'s Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty\n      (BA) vs. BA alone for treatment of tibial vessel disease, defined as \u2265 50 % stenosis of the\n      tibial arteries (AT, PT, TPT, and PR) by angiography.  All subjects will have a\n      corresponding wound being fed by the target vessel which will be assessed during the study.\n      Subjects enrolled in this study may be rolled into the larger pivotal trial, as appropriate."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "General Inclusion Criteria:\n\n          -  Subject's age \u2265 18 years.\n\n          -  Subject is an acceptable candidate for percutaneous intervention with the Sponsor's\n             OAS and BA in accordance with their labeled indications and instructions for use;\n\n          -  Subject is willing and able to sign an approved informed consent form(ICF);\n\n          -  Subject is willing and able to attend follow-up and wound care visits.\n\n        General Exclusion Criteria:\n\n          -  Subject is pregnant or planning to become pregnant within the study period.\n\n          -  Subject is currently participating in an investigational drug or other device study\n             that can clinically interfere with the endpoints of this trial.\n\n          -  Subject has a known sensitivity to contrast media and the sensitivity cannot be\n             adequately pre-medicated.\n\n          -  Uncontrolled allergy to nitinol, stainless steel, or other stent materials.\n\n          -  Subject has known allergy to atherectomy lubricant components such as soybean oil,\n             egg yolk phospholipids, glycerin or sodium hydroxide.\n\n          -  Subject has a history of bleeding diathesis or coagulopathy or will refuse blood\n             transfusions.\n\n          -  Subject has been diagnosed with chronic renal failure or has a creatinine level >\n             2.5, unless on dialysis, prior to the index treatment.\n\n          -  Subject has a planned major surgery (includes major amputation) scheduled within 60\n             days after treatment of the index limb.\n\n          -  Subject has a planned interventional treatment to address stenosis of the\n             contralateral limb scheduled within 60 days after the index treatment.\n\n          -  Subject has a planned interventional treatment to address inflow stenosis of the\n             ipsilateral limb scheduled within 60 days after the index treatment.\n\n          -  Subject has previously had their other limb treated as part of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941030", 
            "org_study_id": "CLARITY I"
        }, 
        "intervention": [
            {
                "arm_group_label": "Orbital Atherectomy System", 
                "description": "Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)", 
                "intervention_name": "Orbital Atherectomy System", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Orbital Atherectomy System", 
                    "Balloon Angioplasty"
                ], 
                "description": "Balloon selection is driven by preference of the operator.", 
                "intervention_name": "Balloon Angioplasty", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Peripheral Artery Disease", 
            "Critical Limb Ischemia", 
            "Orbital Atherectomy", 
            "Balloon Angioplasty", 
            "Intravascular Ultrasound (IVUS)", 
            "Fractional Flow Reserve (FFR)", 
            "Quality of Life"
        ], 
        "lastchanged_date": "September 9, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Dr. Joseph Ricotta, MD, MS, FACS", 
                    "phone": "404-303-3422"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30342"
                    }, 
                    "name": "Northside Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. Nicolas Shammas, MD", 
                    "phone": "563-324-4384", 
                    "phone_ext": "4"
                }, 
                "facility": {
                    "address": {
                        "city": "Davenport", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52803"
                    }, 
                    "name": "Midwest Cardiovascular Research Foundation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. Thomas Davis, MD", 
                    "phone": "586-498-0440"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48236"
                    }, 
                    "name": "St. John Hospital and Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. John Rundback, MD", 
                    "phone": "201-833-3000"
                }, 
                "facility": {
                    "address": {
                        "city": "Teaneck", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07666"
                    }, 
                    "name": "Holy Name Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. George L Adams", 
                    "phone": "919-784-5600"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27607"
                    }, 
                    "name": "Rex Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. Jason Yoho, MD", 
                    "phone": "830-620-1272"
                }, 
                "facility": {
                    "address": {
                        "city": "New Braunfels", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78130"
                    }, 
                    "name": "Mission Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. Marc Glickman, MD", 
                    "phone": "757-470-5570"
                }, 
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }, 
                    "name": "Sentara Vascular Specialists"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Complete Lesion Assessment With ffR and IVUS TechnologY (CLARITY I)", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MAE's are defined for the study as death, major unplanned amputation (above the ankle) of the index limb, and clinically-driven target vessel revascularization (TLR).  MAE's will be collected through 6 months and 12 months post-treatment with the study devices.", 
            "measure": "Rate of Major Adverse Events (MAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months followup and 12 months followup"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Maximum balloon inflation pressure (atm) and time at maximum pressure (sec), rate of stenting, and rate of procedural angiographic complications (dissection, perforation, and distal embolization) will be compared between the two study arms.  Angiography will be assessed by an independent Angio Core Lab.", 
                "measure": "Procedural Parameters", 
                "safety_issue": "No", 
                "time_frame": "Post-orbital atherectomy (OA arm only) and post-balloon angioplasty"
            }, 
            {
                "description": "Technical success is defined for each arm as a final post-procedure result of < 50% residual stenosis by angiography (before stenting, if performed).  Angiography will be assessed by an independent Angio Core Lab.", 
                "measure": "Technical Success", 
                "safety_issue": "No", 
                "time_frame": "Post-orbital atherectomy (OA arm only) and post-balloon angioplasty"
            }
        ], 
        "source": "Cardiovascular Systems Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cardiovascular Systems Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}